<DOC>
	<DOCNO>NCT00101582</DOCNO>
	<brief_summary>The purpose research study test safety effectiveness palifermin determine weekly dos safely administer reduce incidence ( occurrence ) , duration ( length time ) severity ( amount pain ) oral mucositis ( painful sore mouth ) . Mucositis common side effect patient receive chemotherapy ( cancer-killing drug ) radiotherapy ( cancer-killing x-ray ) treatment head neck cancer ( HNC ) .</brief_summary>
	<brief_title>Palifermin Reduction Oral Mucositis Patients With Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>This study consist 2 phase . The acute oral mucositis ( OM ) evaluation phase include time randomization time severe OM ( WHO Grade 3 4 ) resolution ( Week 12 Week 15 participant whose severe OM resolve Week 12 ) . In acute OM evaluation phase , participant randomize receive either single IV dose palifermin placebo 180 Î¼g/kg , 3 day start radiotherapy , plus 7 once-weekly palifermin placebo dose dose level 7-week radio/chemotherapy course . In long-term follow phase , participant follow death , withdrawal consent , loss follow-up . The long-term follow phase still ongoing .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Key Histologically document squamous cell carcinoma involve either oral cavity , oropharynx , nasopharynx , hypopharynx , larynx Newly diagnose , locally advanced stage head neck cancer ( unresectable/unresected disease ) ; American Joint Committee Cancer [ AJCC ] Stage III , IVA IVB amenable radiotherapy concurrent chemotherapy definitive treatment modality At least 50 Gray radiation treatment area oral cavity/oropharynx mucosa visualize Concurrent chemotherapy regimen Cisplatin 100mg/m^2 day 1 , 22 , 43 Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) less equal 2 Adequate hematologic , renal hepatic function Negative pregnancy test serum urine Signed informed consent Key Presence history primary malignancy ( curatively treat situ cervical cancer , basal cell carcinoma skin without evidence disease great 3 year )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>SCCHN</keyword>
	<keyword>Palifermin</keyword>
	<keyword>Mucositis</keyword>
	<keyword>Oral Cavity</keyword>
	<keyword>Oropharynx</keyword>
	<keyword>Nasopharynx</keyword>
	<keyword>Hypopharynx</keyword>
	<keyword>Larynx</keyword>
	<keyword>Mouth Pain</keyword>
	<keyword>Mouth Sores</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Radiochemotherapy</keyword>
	<keyword>Concurrent Chemotherapy</keyword>
	<keyword>Xerostomia</keyword>
	<keyword>Stomatitis</keyword>
	<keyword>Mucosa</keyword>
	<keyword>KGF</keyword>
	<keyword>rHuKGF</keyword>
	<keyword>Keratinocyte Growth Factor</keyword>
	<keyword>HNC</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Oral Mucositis</keyword>
</DOC>